IN2012DN03093A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03093A
IN2012DN03093A IN3093DEN2012A IN2012DN03093A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A IN 3093DEN2012 A IN3093DEN2012 A IN 3093DEN2012A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A
Authority
IN
India
Prior art keywords
construct
host cell
protease
precursor protein
capsid precursor
Prior art date
Application number
Other languages
English (en)
Inventor
Charleston Bryan
Jones Ian
Original Assignee
Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pirbright Inst filed Critical Pirbright Inst
Publication of IN2012DN03093A publication Critical patent/IN2012DN03093A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4704Inhibitors; Supressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3093DEN2012 2009-10-20 2010-09-24 IN2012DN03093A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918375.7A GB0918375D0 (en) 2009-10-20 2009-10-20 Construct
PCT/GB2010/001807 WO2011048353A2 (en) 2009-10-20 2010-09-24 Construct

Publications (1)

Publication Number Publication Date
IN2012DN03093A true IN2012DN03093A (de) 2015-09-18

Family

ID=41462637

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3093DEN2012 IN2012DN03093A (de) 2009-10-20 2010-09-24

Country Status (16)

Country Link
US (1) US9243230B2 (de)
EP (1) EP2491118B1 (de)
JP (1) JP2013507948A (de)
KR (1) KR101818934B1 (de)
CN (1) CN102834507B (de)
AU (1) AU2010309648A1 (de)
BR (1) BR112012009475B1 (de)
CO (1) CO6551678A2 (de)
ES (1) ES2652443T3 (de)
GB (1) GB0918375D0 (de)
HU (1) HUE035889T2 (de)
IN (1) IN2012DN03093A (de)
PH (1) PH12012500662A1 (de)
RU (1) RU2565537C2 (de)
WO (1) WO2011048353A2 (de)
ZA (1) ZA201202882B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
CN107441484A (zh) * 2011-11-03 2017-12-08 森提耐斯特治疗公司 针对人肠道病毒的抗原及疫苗
SG10201810400TA (en) 2012-09-05 2018-12-28 Medicago Inc Picornavirus-like particle production in plants
BR112015024391A2 (pt) 2013-03-26 2017-10-24 The Pirbright Inst mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína
KR20170068410A (ko) * 2014-04-29 2017-06-19 내셔날 헬스 리서치 인스티튜트 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
CN107709554A (zh) * 2015-06-15 2018-02-16 巴法里安诺迪克有限公司 重组经修饰痘苗病毒安卡拉(mva)口蹄疫病毒(fmdv)疫苗
US9975926B2 (en) * 2015-12-08 2018-05-22 The United States of America, as Represented by the Secretary of Homeland Security Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
US10385319B2 (en) 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10308927B2 (en) * 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
WO2019092027A1 (en) * 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
GB201812474D0 (en) * 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Vlp発現cho細胞株の構築
WO2022084426A1 (en) 2020-10-22 2022-04-28 Intervet International B.V. Baculovirus expression vector
US20230390380A1 (en) 2020-10-22 2023-12-07 Intervet Inc. Baculovirus expression vector
IL310908A (en) 2021-08-20 2024-04-01 Intervet Int Bv A virus-like FMDV particle with a stabilizing mutation
CN117881424A (zh) 2021-08-20 2024-04-12 珀布赖特研究所 具有双稳定突变的fmdv病毒样颗粒
EP4387661A1 (de) 2021-08-20 2024-06-26 Intervet International B.V. Verfahren zur herstellung eines virusähnlichen partikels des maul- und klauenseuchevirus
IL310903A (en) 2021-08-20 2024-04-01 Intervet Int Bv Method of producing a foot and mouth disease virus virus-like particle

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712899C1 (de) 1997-03-27 1998-12-10 Christian Dr Probst Verfahren zur Herstellung nichtinfektiöser rekombinanter Picornavirus-Partikel
RU2143921C1 (ru) * 1999-04-21 2000-01-10 Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа а и способ ее изготовления
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1632247A1 (de) 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nukleinsäuren, die für FMDV Proteine kodieren und, die in virus-ähnliche Partikel assemblieren können
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay

Also Published As

Publication number Publication date
GB0918375D0 (en) 2009-12-02
CN102834507A (zh) 2012-12-19
US20120258133A1 (en) 2012-10-11
JP2013507948A (ja) 2013-03-07
AU2010309648A1 (en) 2012-05-03
RU2565537C2 (ru) 2015-10-20
WO2011048353A2 (en) 2011-04-28
CO6551678A2 (es) 2012-10-31
ZA201202882B (en) 2013-06-26
BR112012009475A2 (pt) 2015-09-15
KR101818934B1 (ko) 2018-01-17
PH12012500662A1 (en) 2012-10-22
ES2652443T3 (es) 2018-02-02
HUE035889T2 (en) 2018-05-28
US9243230B2 (en) 2016-01-26
WO2011048353A3 (en) 2011-09-29
EP2491118B1 (de) 2017-11-08
EP2491118A2 (de) 2012-08-29
RU2012120700A (ru) 2013-12-10
BR112012009475B1 (pt) 2020-06-09
CN102834507B (zh) 2016-09-07
KR20120069756A (ko) 2012-06-28

Similar Documents

Publication Publication Date Title
IN2012DN03093A (de)
MX339581B (es) Variantes de subtilasa.
EA201100225A1 (ru) Новые регуляторные элементы
IN2014CN00688A (de)
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
MX336112B (es) Vacunas e inmunoterapicos que usan il-15 optimizada de codones y metodos para usar los mismos.
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
NZ597401A (en) Chimeric influenza virus-like particles comprising hemagglutinin
MX2015014720A (es) Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo.
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2012006096A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
MX369726B (es) Polipéptidos con actividad proteasa.
IN2014DN07017A (de)
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
MX364390B (es) Uso de polipeptidos que tienen actividad proteasa en alimentos para animales y detergentes.
EA201200186A1 (ru) Вектор, содержащий промотор маннозы, и промотор маннозы
MX2014003403A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
WO2010133668A3 (en) Eukaryotic host cell comprising an expression enhancer
MX2014007446A (es) Variantes de subtilasa y polinucleotidos que las codifican.